NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Pharmaceutical Retailers · USD

Scienture Holdings, Inc. (SCNX) Stock Analysis

Scienture Holdings, Inc. (SCNX) is a Pharmaceutical Retailers stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SCNX

$2.91

−$0.15 (−4.75%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SCNX with… →

SCNX Key Statistics

As of Oct 21, 2026
Trading
Open
$3.04
Previous Close
$3.05
Day's Range
2.90–3.10
52-Week Range
2.81–65.00
Volume
24.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
4.08
Valuation
Market Cap
$4.77M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.81
EPS (ttm)Profit attributable to each share over the last twelve months.
−52.75
Financials (FY)
Revenue (FY)
$431.61K+215.87%
Net Income (FY)
−$41.51M−557.90%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.64M
1-Year Return
+464.08%
Dividend and dates
Avg Volume
190.10K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SCNX closed at $2.91, +464.08% over 1 year.

Scienture Holdings, Inc. (SCNX) has a market capitalization of $4.77M.

In fiscal 2025, SCNX reported revenue of $431.61K.

SCNX Stock Return by Calendar Year

Scienture Holdings, Inc. (SCNX) 10-year return: what $10,000 became

1 year
$10,000 $56,408
+464.08%
5 years
$10,000 $709
−92.91%
10 years
$10,000 $740
−92.60%

If you had invested $10,000 in Scienture Holdings, Inc. (SCNX) 10 years ago, at the close on October 21, 2016, it would have been worth $740 at the close on October 21, 2026: −92.60% in total, −22.92% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+469.61%
2025−91.57%
2024+86.91%
2023−14.04%
2022−82.92%
2021−55.39%
2020−19.85%
2019+266.67%
2018−33.33%
2017−2.17%
2016 (partial year)−54.00%

As of October 21, 2026.

SCNX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$431.61K−$41.51M−9,618.0%
2024$136.64K$9.07M6,634.7%
2023$1.36M−$17.84M−1,308.3%
2022$10.25M−$3.47M−33.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$431.61K$331.48K−$16.24M−$41.51M−9,618.0%
2024$136.64K$6.01K−$14.70M$9.07M6,634.7%
2023$1.36M$49.03K−$4.40M−$17.84M−1,308.3%
2022$10.25M$5.52M−$2.04M−$3.47M−33.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SCNX Valuation vs Pharmaceutical Retailers Median

Median of 6 stocks
MetricSCNXPharmaceutical Retailers medianvs median
P/S ratio5.810.2423.9x the median

Medians across 6 Pharmaceutical Retailers stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Scienture Holdings, Inc. (SCNX) carries a market capitalisation of $4.77M. It is classified in the Pharmaceutical Retailers industry, within the Healthcare sector. The company reports 4 employees.

SCNX last closed at $2.91 on October 21, 2026. That is −$0.15 (−4.75%) against the previous close. Over the past 52 weeks the price has ranged from $2.81 to $65.00. The latest close sits 3.38% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $431.61K. Against the prior fiscal year total of $136.64K, that is a change of +215.87%. The same year closed with a net loss of $41.51M. Earnings per share on a trailing basis come to −52.75.

Across the 4 fiscal years on file, revenue moves from $10.25M in 2022 to $431.61K in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 5.81 times revenue. On price-to-sales that is 23.9 times the Pharmaceutical Retailers median of 0.24. 6 Pharmaceutical Retailers companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is +464.08%. Across 10 years the annualized return works out at −22.92%. The reported beta is 4.08. Annualized volatility over the trailing 10 years is 743.98%.

Growth & Income

The latest dividend on file for SCNX dates from 2024.

The strongest complete calendar year on file is 2019 at +266.67%; the weakest is 2025 at −91.57%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the total return is +469.61%.

Peer Comparison

Scienture Holdings, Inc. (SCNX) operates in the Pharmaceutical Retailers industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Scienture Holdings, Inc. SCNX $4.77M —
High Tide Inc. HITI $240.69M —
TelyRx Holdings Inc. TELY.TO CA$66.48M —
Pomdoctor Limited POM $27.90M —

Market caps are shown in each company's own trading currency, without conversion, and the peers are listed in order of these unconverted figures.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Pharmaceutical Retailers Stocks

HITI

High Tide Inc.

$240.69M

 TELY.TO

TelyRx Holdings Inc.

CA$66.48M

 POM

Pomdoctor Limited

$27.90M

 PETS

PetMed Express, Inc.

$25.80M

 RDGT

Ridgetech, Inc.

$2.98M
View all Pharmaceutical Retailers stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Scienture Holdings, Inc.

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.

Visit website →